Hikma Pharmaceuticals PLC 2010 AR2
The report highlights Hikma Pharmaceuticals PLC's strong financial and operational performance in 2010, delivering robust revenue growth of 14.8% to $730.9 million. The company expanded its global presence through strategic acquisitions in Tunisia and Algeria, and signed a transformational agreement to acquire Baxter's US generic injectables business. In sustainability, Hikma continued to align with the UN Global Compact and used the GRI G3 guidelines for the fourth year to measure its environmental and social impacts. Key initiatives included the Global Volunteering Day supporting cancer patients and campaigns raising awareness for diabetes and breast cancer.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2010
Type: AR2
Pages: 132
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's strong financial and operational performance in 2010, delivering robust revenue growth of 14.8% to $730.9 million. The company expanded its global presence through strategic acquisitions in Tunisia and Algeria, and signed a transformational agreement to acquire Baxter's US generic injectables business. In sustainability, Hikma continued to align with the UN Global Compact and used the GRI G3 guidelines for the fourth year to measure its environmental and social impacts. Key initiatives included the Global Volunteering Day supporting cancer patients and campaigns raising awareness for diabetes and breast cancer.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Jan 1, 2010 - Dec 31, 2010
Fiscal Year
2010
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees